|
- Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints - Merck.com
- Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with chemotherapy in adults with metastatic non-small cell lung cancer Merck to discuss results from MK-3475A-D77 study with regulatory authorities worldwide Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ® , together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; “subcutaneous pembrolizumab”), administered with chemotherapy versus intravenous (IV) KEYTRUDA administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell
https://www.merck.com/news/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primary-endpoints/ 당연히 될 거라 생각했고 대한민국 바이오 역사에 남을 기업이라 생각합니다 물론 30에 전부 놓아주었지만... 펩트론이 이어서 해주길 바랍니다 기분이 좋네요 | 
알테오젠 해냈네요40
등록안내
등록안내
0
1
ddfjklsfsfjlkasfjlks
솔직히 한국 제약 바이오 1위라고 봅니다.
이제 곧 실적주가 될텐데 재무 찍히기 시작하면 정말...
상상상 초월이라 생각합니다